HeartBeam, Inc. (NASDAQ: BEAT), a company that specialises in cardiac technology and has created the first and only 3D-vector electrocardiogram (VECG) platform designed for patient use at home, announced that it has extended the SAA between LIVMOR and Samsung by entering into a Strategic Alliance Agreement (SAA) with Samsung. Earlier this year, HeartBeam purchased the assets of LIVMOR.

 

In accordance with the provisions of the contract, HeartBeam and Samsung will identify and specify prospects for cooperation, drawing on the knowledge and patented technology of the HeartBeam team in the evaluation and monitoring of cardiac symptoms.

 

“The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing cutting edge technologies of both Samsung and HeartBeam,” said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder. “Our newly acquired state of the art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo™ telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting.”

 

Kevin Jones, Senior Director, Federal Healthcare, Samsung Electronics America, added, “The strategic collaboration between Samsung and LIVMOR was very successful, resulting in an FDA cleared solution for Atrial Fibrillation detection centered around the Samsung Galaxy watch and tablet running Samsung's defense-grade cyber-security system, Knox. We are excited that LIVMOR is now part of HeartBeam and look forward to continuing our successful collaboration. The potential of combining LIVMOR’s technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans.”